Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays,Science Translational Medicine

当前位置： X-MOL 学术 › Sci. Transl. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
Science Translational Medicine ( IF 15.8 ) Pub Date : 2024-05-15 , DOI: 10.1126/scitranslmed.adl1722
Barbara Mühlemann _{1,

2} , Samuel H Wilks ₃ , Lauren Baracco ₄ , Meriem Bekliz _{5,

6} , Juan Manuel Carreño ₇ , Victor M Corman _{1,

2} , Meredith E Davis-Gardner ₈ , Wanwisa Dejnirattisai _{9,

10} , Michael S Diamond _{11,

12,

13} , Daniel C Douek ₁₄ , Christian Drosten _{1,

2} , Isabella Eckerle _{5,

6,

15} , Venkata-Viswanadh Edara ₈ , Madison Ellis ₈ , Ron A M Fouchier ₁₆ , Matthew Frieman ₄ , Sucheta Godbole ₁₄ , Bart Haagmans ₁₆ , Peter J Halfmann ₁₇ , Amy R Henry ₁₄ , Terry C Jones _{1,

2,

3} , Leah C Katzelnick ₁₈ , Yoshihiro Kawaoka _{17,

19,

20,

21} , Janine Kimpel ₂₂ , Florian Krammer _{7,

23,

24} , Lilin Lai ₈ , Chang Liu _{9,

25} , Sabrina Lusvarghi ₂₆ , Benjamin Meyer ₂₇ , Juthathip Mongkolsapaya _{9,

25} , David C Montefiori _{28,

29} , Anna Mykytyn ₁₆ , Antonia Netzl ₃ , Simon Pollett _{30,

31} , Annika Rössler ₂₂ , Gavin R Screaton _{9,

32} , Xiaoying Shen _{28,

29} , Alex Sigal _{33,

34,

35} , Viviana Simon _{7,

23,

36,

37} , Rahul Subramanian ₃₈ , Piyada Supasa ₉ , Mehul S Suthar ₈ , Sina Türeli ₃ , Wei Wang ₂₆ , Carol D Weiss ₂₆ , Derek J Smith ₃

Affiliation

Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany.
Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.
Center for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Department of Medicine, Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland.
Centre for Emerging Viral Diseases, University Hospitals of Geneva and University of Geneva, CH-1211, Geneva, Switzerland.
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
Division of Emerging Infectious Disease, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Noi, Bangkok 10700, Thailand.
Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Andrew M. and Jane M. Bursky the Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110, USA.
Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, St. Louis, MO 63110, USA.
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Division of Infectious Diseases, Geneva University Hospitals, CH-1211 Geneva, Switzerland.
Viroscience Department, Erasmus Medical Center, 3015 Rotterdam, Netherlands.
Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA.
Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan.
Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), University of Tokyo, Tokyo 162-8655, Japan.
Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Peter-Mayr-Str. 4b, 6020 Innsbruck, Austria.
Department of Pathology, Cellular and Molecular Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford OX3 7BN, UK.
Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, USA.
Centre of Vaccinology, Department of Pathology and Immunology, University of Geneva, CH-1211 Geneva, Switzerland.
Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., Bethesda, MD 20817, USA.
Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Africa Health Research Institute, Durban 4001, South Africa.
School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4001, South Africa.
Centre for the AIDS Programme of Research in South Africa, Durban 4001, South Africa.
Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Office of Data Science and Emerging Technologies, Office of Science Management and Operations, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires ongoing monitoring to judge the ability of newly arising variants to escape the immune response. A surveillance system necessitates an understanding of differences in neutralization titers measured in different assays and using human and animal serum samples. We compared 18 datasets generated using human, hamster, and mouse serum and six different neutralization assays. Datasets using animal model serum samples showed higher titer magnitudes than datasets using human serum samples in this comparison. Fold change in neutralization of variants compared to ancestral SARS-CoV-2, immunodominance patterns, and antigenic maps were similar among serum samples and assays. Most assays yielded consistent results, except for differences in fold change in cytopathic effect assays. Hamster serum samples were a consistent surrogate for human first-infection serum samples. These results inform the transition of surveillance of SARS-CoV-2 antigenic variation from dependence on human first-infection serum samples to the utilization of serum samples from animal models.

中文翻译：

SARS-CoV-2 中和滴度的比较分析揭示了人类和动物模型血清之间以及检测之间的一致性

严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的进化需要持续监测，以判断新出现的变种逃避免疫反应的能力。监测系统需要了解在不同测定中以及使用人类和动物血清样本测量的中和滴度的差异。我们比较了使用人类、仓鼠和小鼠血清以及六种不同的中和测定生成的 18 个数据集。在此比较中，使用动物模型血清样本的数据集显示出比使用人血清样本的数据集更高的滴度值。与祖先 SARS-CoV-2 相比，变体中和的倍数变化、免疫优势模式和抗原图谱在血清样本和检测中相似。除了细胞病变效应测定中倍数变化的差异外，大多数测定产生了一致的结果。仓鼠血清样本是人类首次感染血清样本的一致替代品。这些结果表明 SARS-CoV-2 抗原变异的监测从依赖人类首次感染血清样本转变为利用动物模型的血清样本。

更新日期：2024-05-15

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南